Goldline Pharmaceutical IPO Details
| IPO Open Date | May 12, 2026 |
| IPO Close Date | May 14, 2026 |
| Face Value | ā¹10 Per Equity Share |
| IPO Price Band | ā¹41 to ā¹43 Per Share |
| Issue Size | Approx ā¹12 Crores |
| Fresh Issue | Approx ā¹12 Crores |
| Issue Type | Book build Issue |
| IPO Listing | BSE SME |
| DRHP Draft Prospectus |  |
| RHP Draft Prospectus | |
Goldline Pharmaceutical IPO Review & Key Points
- Review:
Goldline Pharmaceutical IPO Market Lot
The Goldline Pharmaceutical IPO minimum market lot is 6,000 shares with ā¹2,58,000 application amount.
| Application | Lot Size | Shares | Amount |
| Retail Minimum | 2 | 6,000 | ā¹2,58,000 |
| Retail Maximum | 2 | 6,000 | ā¹2,58,000 |
| S-HNI Minimum | 3 | 9,000 | ā¹3,87,000 |
| S-HNI Maximum | 7 | 21,000 | ā¹9,03,000 |
| B-HNI Minimum | 8 | 24,000 | ā¹10,32,000 |
IPO Reservation
| Investor Category | Share Offered | Shares (%) |
| Anchor Investor | – Shares | -% |
| QIB (Ex. Anchor) | – Shares | 50% |
| NII Shares Offered | – Shares | 15% |
| Retail Shares Offered | – Shares | 35% |
Goldline Pharmaceutical IPO Anchor Investors
| Anchor Bidding Date | 2026 |
| Anchor Investors List | |
| Shares Offered | [.] Shares |
| Anchor Size | [.] Cr. |
| lock-in period end date 50% shares (30 Days) | 2026 |
| lock-in period end date 50% shares (90 Days) | 2026 |
Goldline Pharmaceutical IPO Dates
The Goldline Pharmaceutical IPO date is May 12 and the close date is May 14. The Goldline Pharmaceutical IPO allotment will be finalized on May 15 and the IPO listing on May 19.
| IPO Open Date: | May 12, 2026 |
| IPO Close Date: | May 14, 2026 |
| Basis of Allotment: | May 15, 2026 |
| Refunds: | May 18, 2026 |
| Credit to Demat Account: | May 18, 2026 |
| IPO Listing Date: | May 19, 2026 |
| IPO Bidding Cut-off Time: | May 14, 2026 – 5 PM |
Promoters and Holding Pattern
The promoters of the company are Amol Laxmikant Mujumdar and Swapan Premprakash Khandelwal.
| Particular | Shares | % Share |
| Promoter Holding Pre Issue | 69,00,000 | 79.70% |
| Promoter Holding Post Issue | 96,00,000 | -% |
Objects of the Issue & Utilisation of Proceeds
| Purpose | Crores |
| Prepayment or repayment of all or a portion of certain outstanding borrowings availed by our company | ā¹8.90 |
| General Corporate Purpose | ā¹- |
About Goldline Pharmaceutical IPO
To be updated soon
Goldline Pharmaceutical IPO Company Financial Report
Amount ā¹ in Crores
| Period Ended | Revenue | Expense | PAT | Assets |
| 2023 | ā¹19.85 | ā¹19.45 | ā¹0.26 | ā¹19.39 |
| 2024 | ā¹23.57 | ā¹21.04 | ā¹1.81 | ā¹22.93 |
| 2025 | ā¹28.06 | ā¹24.20 | ā¹2.83 | ā¹26.28 |
Goldline Pharmaceutical IPO Valuation – FY2025
Check Goldline Pharmaceutical IPO valuations detail like Earning Per Share (EPS), Price/Earning P/E Ratio, Return on Net Worth (RoNW), and Net Asset Value (NAV) details.
| KPI | Values |
| ROE: | 35.84% |
| ROCE: | 38.46% |
| EBITDA Margin: | 20.79% |
| PAT Margin: | 10.10% |
| Debt to equity ratio: | 1.50 |
| Earning Per Share (EPS): | ā¹4.11 (Basic) |
| Price/Earning P/E Ratio: | N/A |
| Return on Net Worth (RoNW): | 27.38% |
| Net Asset Value (NAV): | ā¹12.39 |
Peer Group Comparison
| Company | EPS | PE Ratio | RoNW % | NAV | Income |
| Mono Pharmacare Limited | 1.75 | 12.57 | 9.90% | 17.66 | 168.34 Cr. |
| Chandra Bhagat Pharma Limited | 1.14 | 37.73 | 2.86% | 39.72 | 86.72 Cr. |
IPO Lead Managers aka Merchant Bankers
- Cumulative Capital Pvt. Ltd.
Company Address
Goldline Pharmaceutical Ltd.
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Phone: +91 712 2786666
Email: info@goldlinepharma.in
Website: http://www.goldlinepharma.in/
IPO Registrar
Bigshare Services Pvt. Ltd.
Phone: +91-22-6263 8200
Email: ipo@bigshareonline.com
Website: https://ipo.bigshareonline.com/IPO_Status.html
Goldline Pharmaceutical IPO FAQs
What is Goldline Pharmaceutical IPO?
Goldline Pharmaceutical IPO is SME IPO. The company is going to raise ā¹12 Crores via IPO. The issue is priced at ā¹41 to ā¹43 per equity share. The IPO is to be listed on BSE.
When Goldline Pharmaceutical IPO will open for subscription?
The IPO is to open on May 12, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 14, 2026.
What is Goldline Pharmaceutical IPO Investors Portion?
The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.
How to Apply the Goldline Pharmaceutical IPO?
You can apply for Goldline Pharmaceutical IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.
What is Goldline Pharmaceutical IPO Issue Size?
Goldline Pharmaceutical IPO issue size is ā¹12 crores.
What is Goldline Pharmaceutical IPO Price Band?
Goldline Pharmaceutical IPO Price Band is ā¹41 to ā¹43.
What is Goldline Pharmaceutical IPO Lot Size?
The minimum bid is 6,000 Shares with ā¹2,58,000 amount.
What is the Goldline Pharmaceutical IPO Allotment Date?
Goldline Pharmaceutical IPO allotment date is May 15, 2026.
What is the Goldline Pharmaceutical IPO Listing Date?
Goldline Pharmaceutical IPO listing date is May 19, 2026. The IPO is to list on BSE.
Note: The Goldline Pharmaceutical IPO price band and date are officially announced. The (Goldline Pharmaceutical IPO grey market premium) will be added to the IPO GMP page as it will start).
